Education
About Us
Working with TipRanks
Follow Us
Aquestive Therapeutics, Inc. (AQST)
NASDAQ:AQST
Total Valuation
Aquestive Therapeutics has a market cap or net worth of $490.62M. The enterprise value is $409.49M.
Market Cap$490.62M
Enterprise Value$409.49M
Share Statistics
Aquestive Therapeutics has 122,045,050 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding122,045,050
Owned by Insiders2.94%
Owned by Institutions23.66%
Financial Efficiency
Aquestive Therapeutics’s return on equity (ROE) is 2.49 and return on invested capital (ROIC) is -57.10%.
Return on Equity (ROE)2.49
Return on Assets (ROA)-0.52
Return on Invested Capital (ROIC)-57.10%
Return on Capital Employed (ROCE)-0.63
Revenue Per Employee313.70K
Profits Per Employee-590.03K
Employee Count142
Asset Turnover0.28
Inventory Turnover3.01
Valuation Ratios
The current PE Ratio of Aquestive Therapeutics is ―. Aquestive Therapeutics’s PEG ratio is -0.19.
PE Ratio―
PS Ratio17.69
PB Ratio-23.41
Price to Fair Value-23.41
Price to FCF-14.87
Price to Operating Cash Flow-9.35
PEG Ratio-0.19
Income Statement
In the last 12 months, Aquestive Therapeutics had revenue of 44.55M and earned -83.78M in profits. Earnings per share was -0.76.
Revenue44.55M
Gross Profit25.99M
Operating Income-71.05M
Pretax Income-83.78M
Net Income-83.78M
EBITDA-70.49M
Earnings Per Share (EPS)-0.76
Cash Flow
In the last 12 months, operating cash flow was -52.43M and capital expenditures -562.00K, giving a free cash flow of -52.99M billion.
Operating Cash Flow-52.43M
Free Cash Flow-52.99M
Free Cash Flow per Share-0.43
Dividends & Yields
Aquestive Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.70
52-Week Price Change40.56%
50-Day Moving Average4.11
200-Day Moving Average4.75
Relative Strength Index (RSI)47.06
Average Volume (3m)4.54M
Important Dates
Aquestive Therapeutics upcoming earnings date is May 5, 2026, After Close (Confirmed).
Last Earnings DateMar 4, 2026
Next Earnings DateMay 5, 2026
Ex-Dividend Date―
Financial Position
Aquestive Therapeutics as a current ratio of 3.14, with Debt / Equity ratio of -390.48%
Current Ratio3.14
Quick Ratio3.01
Debt to Market Cap0.16
Net Debt to EBITDA-0.15
Interest Coverage Ratio-4.16
Taxes
In the past 12 months, Aquestive Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Aquestive Therapeutics EV to EBITDA ratio is -11.32, with an EV/FCF ratio of -15.06.
EV to Sales17.92
EV to EBITDA-11.32
EV to Free Cash Flow-15.06
EV to Operating Cash Flow-15.22
Balance Sheet
Aquestive Therapeutics has $121.17M in cash and marketable securities with $131.44M in debt, giving a net cash position of -$10.28M billion.
Cash & Marketable Securities$121.17M
Total Debt$131.44M
Net Cash-$10.28M
Net Cash Per Share-$0.08
Tangible Book Value Per Share-$0.28
Margins
Gross margin is 58.35%, with operating margin of -159.50%, and net profit margin of -188.09%.
Gross Margin58.35%
Operating Margin-159.50%
Pretax Margin-188.09%
Net Profit Margin-188.09%
EBITDA Margin-158.25%
EBIT Margin-159.50%
Analyst Forecast
The average price target for Aquestive Therapeutics is $8.86, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$8.86
Price Target Upside120.40% Upside
Analyst ConsensusStrong Buy
Analyst Count7
Revenue Growth Forecast-26.32%
EPS Growth Forecast-56.54%